Nanni C.,U.O. Nuclear Medicine |
Errani C.,Rizzoli Orthopaedic Institute |
Boriani L.,Rizzoli Orthopaedic Institute |
Fantini L.,U.O. Nuclear Medicine |
And 7 more authors.
Journal of Nuclear Medicine | Year: 2010
The aim of this work was to preliminarily evaluate the sensitivity, specificity, positive predictive value, negative predictive value, and overall accuracy of 68Ga-citrate PET/CT in a population of patients with suspected bone infections. Methods: We enrolled 31 patients with suspected osteomyelitis or diskitis who underwent a total of forty 68Ga-citrate PET/CT scans. The results were compared with different combinations of diagnostic procedures (MRI, radiography, CT, or white blood cell scintigraphy), biopsy (when diagnostic), and follow-up data (at least 1 y) to determine the performance of 68Ga-citrate PET/CT. Results: We found a sensitivity of 100%, a specificity of 76%, a positive predictive value of 85%, a negative predictive value of 100%, and an overall accuracy of 90%. Conclusion: Although preliminary, these data confirm a possible role for 68Ga-citrate in the diagnosis of bone infections, especially in consideration of its favorable characteristics. Copyright © 2010 by the Society of Nuclear Medicine, Inc. Source
Specchio L.M.,University of Foggia |
D'Orsi G.,University of Foggia |
Demaio V.,Opera Don Uva |
Pacillo F.,University of Foggia |
And 7 more authors.
Bollettino - Lega Italiana contro l'Epilessia | Year: 2011
Smile is a rare and uncommon ictal manifestation in partial seizures. We have investigated the ictal clinical, EEG and SPECT correlations in two patients with cryptogenic focal epilepsy and epileptic smile. In our patients, ictal smile, not associated with the feeling of happiness, is the main clinical manifestation of focal seizures with a right temporal epileptogenic region. Our findings may suggest that (right) temporal region may be involved in the control of smiling facial expressions. Source
Capobianco M.,Centro Of Riferimento Regionale Sclerosi Multipla |
Piccoli G.,University of Turin |
Vigotti F.N.,University of Turin |
Scapoli P.,Medicina Nucleare |
And 4 more authors.
Multiple Sclerosis Journal | Year: 2014
We report on a so-far never described association between glomerulonephritis and sarcoid-like lung disease after longterm interferon beta (IFNb) treatment for relapsing-remitting multiple sclerosis. The interest in this case resides in the documented remission after IFNb discontinuation. The history of IFNb-related adverse events is probably not yet completely written. The rapid reversal of the pathological signs in our patient underlines the importance of careful clinical and laboratory surveillance, including kidney functional parameters, for an early diagnosis of IFNb-related diseases. © The Author(s) 2014. Source
Foppiani L.,Science Medicina Interna |
Antonucci G.,Area Critica di Medicina |
Scirocco M.C.,Science Medicina Interna |
Lione S.,Science Medicina Interna |
And 4 more authors.
Recenti Progressi in Medicina | Year: 2014
Primary hyperparathyroidism is a common endocrinopathy which is nowadays diagnosed incidentally. Calcium levels range from "normal" to extremely high which can be life-threatening. We report the case of a female patient who was admitted to hospital for unspecific symptoms ultimately referable to severe hypercalcemia secondary to a large parathyroid tumor. After an intensive medical treatment (hydration, diuretics, steroids, bisphosphonate) leading to reduction of calcium levels, the patient underwent surgery with exeresis of the parathyroid mass proved an adenoma and normalization of calcium levels; nevertheless a few days after discharge symptomatic hypocalcemia occurred and was successfully managed by means of calcium and vitamin D therapy which is still required three months after surgery. Copyright - Il Pensiero Scientifico Editore. Source
Roelcke U.,Brain Tumor Center |
Wyss M.T.,University of Zurich |
Nowosielski M.,Innsbruck Medical University |
Ruda R.,University of Turin |
And 7 more authors.
Neuro-Oncology | Year: 2016
Background. Patients with WHO grade II glioma may respond to chemotherapy that is currently not standardized regarding timing and treatment duration. Metabolic changes during chemotherapy may precede structural tumor volume reductions. We therefore compared time courses of amino acid PET and MRI responses to temozolomide (TMZ) and assessed whether responses correlated with seizure control and progression-free survival (PFS). Methods. PET and MRI were performed before and during TMZ chemotherapy. Tumor volumes were calculated using regions-of-interest analysis. Amino acid uptake was also quantified as metabolically active tumor volume and tumor-to-cerebellum uptake ratio. Results. One hundred twenty-five PET and 125 MRI scans from 33 patients were analyzed. Twenty-five patients showed metabolic responses that exhibited an exponential time course with a 25% reduction of the active volume on average after 2.3 months. MRI responses followed a linear course with a 25% reduction after 16.8 months. Reduction of metabolically active tumor volumes, but not reduction of PET uptake ratios or MRI tumor volumes, correlated with improved seizure control following chemotherapy (P =. 012). Receiver-operating-characteristic curve analysis showed that a decrease of the active tumor volume of ≥80.5% predicts a PFS of ≥60 months (P =. 018) and a decrease of ≥64.5% a PFS of ≥48 months (P =. 037). Conclusions. Amino acid PET is superior to MRI for evaluating TMZ responses in WHO grade II glioma patients. The response delay between both imaging modalities favors amino acid PET for individually tailoring the duration of chemotherapy. Additional studies should investigate whether this personalized approach is appropriate with regard to outcome. © 2015 The Author(s). Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. Source